This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CP-675,206, CP-675206, ticilimumab
Description: Tremelimumab is a monoclonal antibody that acts by blocking a key negative regulator of the activity of the immune system. This regulator, cytotoxic T lymphocyte-associated antigen 4 (CTLA4), stops activated immune cells from attacking the body's own tissues. The antibody, in turn, stops the function of CTLA4, a receptor that works as the brakes of the immune system.
Pfizer and Medarex
In September 2004, Medarex entered into a series of agreements with Pfizer. The first agreement amended Medarex's existing collaborative research and license and royalty agreements with Pfizer to provide for the discovery and development of up to 50 antibody products over ten years. The second and third agreements were a sublicense by Medarex to Pfizer and a cross-license of certain patents and patent applications solely relating to Medarex's respective anti-CTLA-4 antibody programs. The fourth agreement was a stock purchase agreement also related to the anti-CTLA-4 programs. Pfizer made an initial cash payment to Medarex of $80 million and purchased a total of 4,827,808 unregistered shares of common stock at $6.21/share. Pfizer agreed to a two-year lock-up period with respect to any sales of such stock.
Medarex expects to use UltiMAb Human Antibody Development System to generate product candidates to disease-associated targets identified by Pfizer....See full deal structure in Biomedtracker
Partners: Amgen, Inc. Bristol-Myers Squibb Company Pfizer Inc.
Additional information available to subscribers only: